PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT06079320
- Locations
- 🇺🇸
National Institute of Clinical Research, Westminster, California, United States
🇺🇸Adult Medicine of Lake County, Inc., Mount Dora, Florida, United States
🇺🇸Adult Medicine of Lake County, Mount Dora, Florida, United States
A Study to Learn About ABRYSVO Vaccine in Older Adults to Prevent Severe Respiratory Syncytial Virus (RSV) Disease
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Biological: Prior standard of care receipt of Pfizer's ABRYSVO vaccine
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06077968
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
- Conditions
- Stable Nonsegmental VitiligoActive Nonsegmental Vitiligo
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1450
- Registration Number
- NCT06072183
- Locations
- 🇺🇸
FXM Clinical Research - Miramar, Miramar, Florida, United States
🇺🇸GCP Research, Global Clinical professionals, Saint Petersburg, Florida, United States
🇺🇸USF Health, Tampa, Florida, United States
A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: dacomitnib
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT06075615
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: Novel hormonal therapy
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3017
- Registration Number
- NCT06072196
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT06067191
- Locations
- 🇬🇧
Pfizer, London, United Kingdom
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT06057402
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
ATGAM General Investigation
- Conditions
- Aplastic Anemia
- Interventions
- Drug: Anti-human thymocyte immunoglobulin, equine
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06039020
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
- Conditions
- Renal Impairment
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT06037031
- Locations
- 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Genesis Clinical Research, LLC, Tampa, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT06033612
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, Greater London, United Kingdom